Division of Sanofi
Latest From Chattem Inc.
Sanofi and GSK appeal Council of Better Business Bureaus investigative arm's recommendations from review of ACT Dry Mouth ad claims. GSK disagrees that Sanofi's could continue using a claim of "moisturizes dry mouth" and Sanofi disagrees that it did not substantiate claims that established ACT Dry Mouth, marketed with cavity prevention claims, as providing benefits similar to GSK's Biodene, which has pre-market approval for an indication of lubricating and coating the interior of the mouth and gums with moisture.
Biodene maker GSK challenged Sanofi's ACT Dry Mouth advertising and both companies find disappointments in the Better Business Bureaus' advertising division's review.
French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.
Sales of dietary supplements promoted for nutritional needs of diabetics are exploding as consumers seek non-drug products to deal with symptoms of the disease, says a consumer health analyst in a recent presentation. Consumer health products positioned to prevent disease are growing at a much faster rate globally than those formulas that treat ailments.
- OTC, Consumer
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
- Contact Info
Phone: (615) 821-4571
1715 West 38th St.
P.O. Box 2219 Chattanooga, TN 37409
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.